Genetron Holdings Limited (“Genetron Health” or the “Company”,
Nasdaq: GTH), a leading precision oncology platform company in
China that specializes in offering molecular profiling tests, early
cancer screening products and companion diagnostics development,
today announced the release of 17 research results at the American
Association for Cancer Research Annual Meeting 2022 (AACR 2022).
The results emerged from joint studies that Genetron Health
conducted with more than 20 leading hospitals in China, which
leveraged the Company's "One-step Seq" patented technology, core
products such as the multi-gene NGS panel testing - Onco PanScan™
and the comprehensive sarcoma gene testing - Onco PanScan plus™.
These studies involved an in-depth analysis of the Chinese
population, covering lung cancer, gastric cancer, colon cancer,
bladder cancer, glioma, sarcoma, and other types of cancer. More
specifically, the studies focused on characteristics of each
cancer, including mutation, fusion characteristics, hereditary
tumor biomarkers, immunotherapy-associated biomarker screening, and
molecular detection guidance of clinical typing, diagnosis and
treatment, contributing to the scientific research and full-cycle
clinical management of cancer.
“These results presented by Genetron Health at AACR 2022, which
are all based on the Company's innovative technologies and
products, explore the characteristics of multi-cancer genomics, and
the clinical application of products,” said Dr. Yunfu Hu, Genetron
Health’s Chief Medical Officer. “For example, by using Onco PanScan
plus™ integrated DNA and RNA, we studied the genetic variation in
sarcomas of children and adults. It revealed the genetic variation
and HRR gene mutations in sarcomas, which provided evidence for the
potential use of PARP inhibitors in sarcoma patients. Adopting the
Company's Onco Urine™ test, in the study of patients with
muscle-invasive bladder cancer (MIBC) neoadjuvant immunotherapy, we
found urine genetic detection has the potential to assess the
pathological response of patients. With Onco PanScan™, we conducted
a study into POLE/POLD1, MMR, MSI, TMB which are related to
immunotherapy and found that ACVR2ALOF was associated with MSI
variation in gastric and colorectal cancers.”
“In the future, Genetron Health's products and technologies will
continue to contribute to the early diagnosis and clinical
treatment of cancer patients,” Hu added.
All 17 studies shared by Genetron Health at the AACR 2022
focused mainly four areas, as following:
Gene mutation and fusion mapping research help clinical
classification and personalized treatment
Five studies (#5756, #5755, #5746, #5575, #5771) were based on
retrospective Next-Generation Sequencing (NGS) results. By
conducting gene mutation and fusion mapping in children and adults
of the sarcoma genome, sarcoma HRR gene, glioma fusion, solid tumor
BRAF and RAF1 fusions, and lung cancer RTK fusions, the studies
aimed to explore the molecular characteristics related to cancer,
thereby providing diagnosis and guidance of tumor classification
and personalized treatment.
Molecular detection guides clinical diagnosis and
treatment
Glioblastoma (GBM) is the most common malignant brain tumor.
Patients with GBM normally have a poor prognosis and a high risk of
recurrence. Study #5264 reported the rare case of a patient with
GBM that recurred two years after surgical resection and was
diagnosed with low-grade astrocytoma based on histopathological
features. However, the molecular characteristics indicated that the
recurrent tumor should be diagnosed as a high-grade GBM, thus
demonstrating the clinical importance of combining
histopathological features with molecular features for
diagnosis.
Radical cystectomy (RC) is the standard treatment for
muscle-invasive bladder cancer (MIBC), but it greatly affects the
patient’s quality of life, even if a urinary tract diversion is
made. Study #5101 reported the case of an MIBC patient who received
RC treatment with urine-based dynamic monitoring during the period
of neoadjuvant immunotherapy, and the result indicated that dynamic
monitoring could reflect complete pathological remission. The
findings will help the selection of patients for bladder
preservation treatment and personalized care.
HER2 antibody trastuzumab combined with chemotherapy is the
frontline treatment option for patients with HER2-positive breast
or gastric cancer. This option recently showed antitumor activity
in patients with HER2-positive gallbladder cancer (GBC). However,
there is currently no effective way to deal with the drug
resistance to targeted therapy of HER2-positive GBC. Study #5517
reported a patient with HER2-positive metastatic GBC who was
refractory to trastuzumab combined with chemotherapy, but had
significant clinical benefits with the additional use of the PD-1
antibody camrelizumab. The results showed the significance of the
combination of immunotherapy and HER2-targeted therapy in the
treatment of HER2-positive GBC.
Hereditary tumor biomarkers guide early screening and
diagnosis of diseases
Four studies (#5840, #5875, #5777, #5778) explored pathogenic
germline mutations in gliomas, sarcomas, and gastric cancers
including HRR and MMR core genes and other key susceptibilities to
hereditary genes, providing instructional guidance to early disease
diagnosis, genetic counseling and treatment.
Immunotherapy marker screening plus immunotherapy
population screening
Five studies (#5292, #5774, #5751, #5197, #5752) discussed the
correlation of BRAF, POLE/POLD1, clock genes, and ACVR2ALOF with
MMR, TMB, etc., which could be used as potential biomarkers for
immunotherapy.
Abstract# |
Title |
5264 |
Glioblastoma degraded to
low-grade astrocytoma two-years after surgical resection: A
rare case report |
5292 |
Investigating the Potential Relationship between BRAF Mutations and
Tumor Mutation Burden (TMB) in Lung Cancer (LC) |
5774 |
Investigating the characteristics of BRAF mutations and its
potential relationship with therapy in a large Chinese Lung Cancer
cohort |
5746 |
Analysis of molecular characteristics of gliomas harboring gene
fusions |
5751 |
Comprehensive analysis of POLE/POLD1 variants, MMR deficient/MSI,
and tumor mutational burden in Chinese population |
5752 |
Loss-of-function mutations in ACVR2A are correlated with
microsatellite instability in gastric and colorectal
cancer |
5755 |
Mutation profiling of homologous recombination-related (HRR) genes
in Chinese sarcoma patients |
5840 |
The characteristics of TP53 germline mutations analyzed in a
large-scale cohort of Chinese glioma patients |
5756 |
Next-Generation Sequencing (NGS) reveals differences in molecular
profiles of pediatric sarcoma in children and adults |
5575 |
Landscape of BRAF and RAF1 fusions identified by next‑generation
sequencing in a Chinese multi-cancer retrospective analysis |
5875 |
Germline gene alterations in high grade and low grade gliomas: A
multi-center, large scale study in China |
5517 |
Addition of PD-1 antibody camrelizumab overcame resistance to
trastuzumab plus chemotherapy in a HER2-positive, metastatic
gallbladder cancer patient |
5778 |
Early-onset of double germline mutations in homologous
recombination deficiency (HRD)-mutated gastric cancer |
5777 |
Germline variants of cancer predisposition genes in a large cohort
of Chinese sarcoma patients |
5101 |
Urine based dynamically monitoring reflect pathologic response in
MIBC patients with neoadjuvant immunotherapy |
5771 |
The refined stratification of receptor tyrosine kinase fusions in
lung cancer |
5197 |
Alterations of the circadian
clock genes and their association with tumor mutation burden
and response to immunotherapy in NSCLC |
About Genetron Holdings Limited
Genetron Holdings Limited (“Genetron Health” or the “Company”)
(Nasdaq: GTH) is a leading precision oncology platform company in
China that specializes in cancer molecular profiling and harnesses
advanced technologies in molecular biology and data science to
transform cancer treatment. The Company has developed a
comprehensive oncology portfolio that covers the entire spectrum of
cancer management, addressing needs and challenges from early
screening, diagnosis and treatment recommendations, as well as
continuous disease monitoring and care. Genetron Health also
partners with global biopharmaceutical companies and offers
customized services and products. For more information, please
visit ir.genetronhealth.com.
Safe Harbor Statement
This press release contains forward-looking statements. These
statements are made under the “safe harbor” provisions of the U.S.
Private Securities Litigation Reform Act of 1995. Statements that
are not historical facts, including statements about the Company’s
beliefs and expectations, are forward-looking statements.
Forward-looking statements involve inherent risks and
uncertainties, and a number of factors could cause actual results
to differ materially from those contained in any forward-looking
statement. In some cases, forward-looking statements can be
identified by words or phrases such as “may”, “will,” “expect,”
“anticipate,” “target,” “aim,” “estimate,” “intend,” “plan,”
“believe,” “potential,” “continue,” “is/are likely to” or other
similar expressions. Further information regarding these and other
risks, uncertainties or factors is included in the Company’s
filings with the SEC. All information provided in this press
release is as of the date of this press release, and the Company
does not undertake any duty to update such information, except as
required under applicable law.
Investor Relations ContactHoki LukEmail:
hoki.luk@genetronhealth.comPhone: +1 (408) 891-9255
Philip Trip TaylorVice President | Gilmartin
Groupir@genetronhealth.com
Media Relations Contact
Yanrong ZhaoGenetron HealthEmail:
yanrong.zhao@genetronhealth.com
Edmond LococoICREdmond.Lococo@icrinc.comMobile: +86
138-1079-1408genetron.pr@icrinc.com
Genetron (NASDAQ:GTH)
Historical Stock Chart
From May 2024 to Jun 2024
Genetron (NASDAQ:GTH)
Historical Stock Chart
From Jun 2023 to Jun 2024